Pharmacodynamics
tumor
DISEASE, TUMOR
T cell activation, using the early activation marker CD69, was not observed after polatuzumab vedotin administration alone. However, percentages of both CD69B cell recovery was assessed given that the mosun-pola regimen targets two distinct B cell lineage markers. B cell counts were evaluated in patients who achieved a complete response. Patients with partial response or stable disease were excluded from the analysis, as circulating tumor B cells and loss of long-term follow-up at time of progression could confound interpretation. Twenty-seven patients who achieved a complete response and had at least one B cell measurement at baseline, during treatment and during the follow-up period were included in this subset analysis. The median follow-up was 25 months (range, 13.5–35.9) for these 27 patients. Median time to B cell recovery, defined as CD19